Table 1.
Depth of burns: PT: partial thickness, FT: full thickness, S: superficial; HBO: hyperbaric oxygenation; NBO: normobaric oxygenation; THAM: Tris (hydroxymethyl) aminomethane buffer.
| Author/Year | Species | Nr. Individuals | Study Design | % TBSA | Depth of Burn | Local Treatment |
|---|---|---|---|---|---|---|
| Marchal/1966 | Rats | 187 | no burn/HBO: 10 | |||
| burn/untreated: 15; burn/HBO: 15 | 20 | FT | ||||
| 7 arm (at least 21 each;) burn/no treatment burn/HBO only burn/saline burn/saline, HBO burn/THAM burn/THAM, HBO (each day) burn/THAM, HBO (every other day) |
75 | PT | ||||
| Nelson/1966 | Dogs | 24 | 2 arm; burn/untreated: 12 burn/HBO: 12 |
75 | PT | |
| Ketchum/1967 | Rabbits | 26 | 2 arm; burn/untreated: 13; burn/HBO: 13 |
5 | FT, PT | |
| Ketchum/1970 | Rats | 30 | 2 arm; burn/untreated: 15 burn/HBO: 15 |
20 | FT | |
| Benichoux/1968 | Rats | 160 | 8 arm; no burn/HBO: 10 burn/no treatment: 25 burn/HBO only: 25 burn/saline: 25 burn/saline, HBO: 25 burn/THAM: 25 burn/THAM, HBO every day: 25 burn/THAM, HBO every second day: 25 |
75 | PT | |
| 200 | 8 arm; no burn/HBO; burn/THAM; burn/HBO every second day; burn/colmycine, penicilline; burn/THAM, HBO; burn/penicilline, colimycin, HBO; burn/THAM, penicilline, colimycine burn/THAM, penicillin, colimycine, HBO |
30 | PT | |||
| Perrins/1969 | Pigs | 8 | 2 arm; burn/untreated: 4 burn/HBO: 4 |
12 | FT | |
| 4 | 2 arm; burn/untreated: 2 burn/HBO: 2 |
8 | PT | |||
| Spinadel/1969 | Guinea pigs | 99 | 3 arm; burn/untreated: 33 burn/antibiotics 33 burn/HBO & antibiotics: 33 |
25 | PT | Gentamycin-powder |
| Hamsters | 75 | 3 arm; burn/untreated: 25 burn/antibiotics: 25 burn/HBO & antibiotics: 25 |
25 | PT | Gentamycin-powder | |
| Gruber/1970 | Rats | 24 | 3 arm; pedicled flap, replanted/HBO: 8 composite skin graft, replanted/HBO: 8; burn/HBO: 8 |
10 | FT | |
| Bleser/1971 | Rats | 520 | 3 arm; no burn/untreated: 20 burn/untreated: 250 burn/HBO, THAM, penicillin, colimycine: 250 |
32 | PT | |
| Bleser/1973 | Rats | 100 | 2 arm; burn/untreated: 50 burn/HBO: 50 |
5 | FT | |
| Härtwig/1974 | Rats | 100 | 2 arm; burn/untreated: 50 burn/HBO: 50 |
2 | FT | |
| Korn/1977 | Guinea pigs | 117 | Series I: 3 arm; burn/HBO: 52 burn/Hyperbaric normoxia: 27 burn/untreated: 38 |
5 | PT | open/pro-tected |
| 54 | Series II: 2 arm; burn/HBO: 30 burn/untreated: 24 |
5 | PT | open/pro-tected | ||
| 40 | Series III: 4 arm; no burn/control: 8 no burn/HBO: 8 burn/untreated: 12 burn/HBO: 12 |
5 | PT | open/pro-tected | ||
| Niccole/1977 | Rats | 80 | 4 arm; burn/untreated: 20 burn/HBO: 20 burn/sliver-sulfadiazine: 20 burn/HBO/silver-sulfadiazine: 20 |
20 | 40 PT 40 FT |
sulfadiazine (removed before HBO); no dressings |
| Wells/1977 | Dogs | 24 | 3 arm; burn/no fluid: 8 burn/no fluid, NBO: 8 burn/fluid, HBO: 8 |
40 | FT | |
| Arzinger-Jonasch/1978 | Guinea pigs | 120 | 5 arm; burn/HBO: 10 |
15 | PT | |
| burn/HBO: 10 | FT | |||||
| burn/HBO: 20; necrectomy at various time points | FT | necrectomy | ||||
| burn/HBO: 20; necrectomy, full-thickness grafts at various time points | FT | necrectomy/skin graft | ||||
| burn/necrectomy, full-thickness grafts at various time time points: 60; | FT | necrectomy/skin graft | ||||
| Nylander/1984 | Mice | 54 | 2 arm; burn/untreated: 27 burn/HBO: 27 |
6 | PT | |
| Kaiser/1985 | Guinea pig | 102 | 5 arm: burn not infected/untreated: 21 burn not infected/HBO: 21 burn infected (pseudomonas)/untreated: 30 burn infected (pseudomonas)/primary HBO: 15 burn infected (pseudomonas)/secondary HBO: 15 |
5 | FT | |
| Kaiser/1988 | Guinea pigs | 75 | 2 arm; burn/untreated: 43 burn/HBO: 32 |
5 | PT | |
| Stewart/1989 | Rats | 90 | 15 arm; no burn/untreated: 6 |
|||
| burn/untreated, biopsy at 12 h: 6 | 5 | PT | silver sulfadiazine | |||
| burn/1 HBO, biopsy at 12 h: 6 | PT | |||||
| burn/2 HBO, biopsy at 12 h: 6 | PT | |||||
| burn/1HBO biopsy at 36 h: 6 | PT | |||||
| burn/untreated, biopsy; 5 groups of 6 animals each at 36, 48, 72, 96 or 120 h | PT | |||||
| burn/2 HBO, biopsy; 5 groups of 6 animals each at 36, 48, 72, 96 or 120 h | PT | |||||
| Saunders/1989 | Guinea pigs | 30 | 2 arm; burn/untreated: 15 burn/HBO: 15 (3 different times of evaluation: 6, 24, 48 h) |
PT | ||
| Tenenhaus/1994 | Mice | 125 | 5 arm; no burn/fluid, food: 22 burn/fluid, food: 32 burn/fluid, food, compressed air: 15 burn/, fluid, food, NBO: 24 burn/fluid, food, HBO: 32 |
32 | FT | |
| 139 | 4 arm; no burn/fluid, no food: 22 burn/fluid, no food: 51 burn/fluid, no food, HBO 2 × 120 min: 57 burn/fluid, no food, HBO 3 × 120 min: 9 |
32 | FT | |||
| Espinosa/1995 | Guinea pigs | 20 | 3 arm; burn/untreated: 6 burn/HBO: 7 burn/HBO, antibiotic: 7 |
10 | PT | |
| Hussmann/1996 | Rats | 74 | 11 arm; no burn/untreated: 4 |
10 | FT | |
| no burn/anaesthesia, untreated: 7 | ||||||
| burn/untreated: 7 | FT | |||||
| excision of 10% TBSA/suture: 7 | excision | |||||
| no burn/HBO (acute): 7 | ||||||
| no burn/HBO (chronical): 7 | ||||||
| burn/excision after 4 h: 7 | FT | excision | ||||
| burn/HBO (once): 7 | FT | |||||
| burn/HBO (repeated): 7 | FT | |||||
| burn/excision after 4 h and HBO (once): 7 | FT | excision | ||||
| burn/excision after 4 h and HBO (repeated): 7 | FT | excision | ||||
| Germonpré/1996 | Rats | 46 | 3 arm; burn/untreated: 10 burn/HBO: 17 burn/Piracetam: 19 |
5 | PT | mafenide gauze; Op-Site |
| Shoshani/1998 | Guinea pigs | 54 | 3 arm; burn/silversulfadiazine: 18 burn/NBO, silversulfadiazine: 18 burn/HBO, silversulfadiazine: 18 |
5 | PT | silver sulfadiazine |
| Akin/2002 | Rats | 54 | 7 arm; no burn/liquids: 6 no burn/liquids, HBO (short): 8 no burn/liquids, HBO (long): 8 burn/liquids: 16 burn/liquids, HBO (short): 8 burn/liquids, HBO long): 8 |
30 | PT | |
| Bilic/2005 | Rats | 70 | 2 arm randomized; burn/Hyperbaric normoxia: 35 burn/HBO: 35 |
20 | PT | silver sulfadiazine |
| Türkaslan/2010 | Rats | 20 | 4 arm; burn/untreated (evaluation at 24 h): 5 burn/HBO (evaluation at 24 h): 5 burn/untreated (evaluation on day 5): 5 burn/HBO (evaluation on day 5): 5 |
5 | PT | |
| Selcuk/2013 | Rats | 32 | 4 arm; burn/Nicotine, HBO: 8, burn/Nicotine: 8; burn/no nicotine/HBO: 8; burn/no Nicotine: 8 | 12 | PT, FT | |
| Wu/2018 | Rats | 36 | 6 arm; sham-burn/sham HBO: 6 sham burn/HBO: 6 burn/1 week sham HBO: 6 burn/2 week sham HBO:6 burn/1 week HBO: 6 burn/2 weeks HBO: 6 |
1 | FT | silver sulfadiazine |
| Wu/2019 | Rats | 30 | 5 arm; Sham-burn/Sham HBO: 6; sham burn/HBO: 6; burn/1 week sham HBO:6; burn/1 week HBO: 6; burn/2 weeks HBO: 6 |
1 | FT | silver sulfadiazine |
| Hatibie/2019 | Rabbits | 36 | 2 arm; burn/untreated; 18 burn/HBO: 18 |
1 | PT | vaseline |
| Ikeda/1967 | Patients | 43 | case series | >50 | PT, FT | silver nitrate 0,5% |
| Lamy/1970 | Patients | 27 | case series, historical comparator | 20 to >80 | PT, FT | |
| Hart/1974 | Patients | 191 | 2 arm double blind randomized; (included in observational 138 burn/HBO: 138 and burn/sham HBO: 53) | 10 to 50 | PT, FT | silver sulfadiazine |
| Group I (HBO: 2; sham HBO: 2) | >10 <20 | |||||
| Group II (HBO: 2; sham HBO: 2) | >20 <30 | |||||
| Group III (HBO: 2; sham HBO: 2) | >30 <40 | |||||
| Group IV (HBO: 2; sham HBO: 2) | <40 <50 | |||||
| Grossmann/1978 | Patients | 821 | 2 arm; nonrandomized controls; burn/routine treatment: 419; burn/routine treatment & HBO: 421 |
>20 <80 | PT, FT | silver sulfadiazine |
| Waisbren/1982 | Patients | 72 | 2 arm: matched pairs; burn/routine treatment: 36; burn/routine treatment & HBO: 36 |
about 50 | PT, FT | |
| Niu/1987 | Patients | 835 | 2 arm; nonrandomized comparator; burn/routine treatment: 609; burn/routine treatment & HBO: 226 |
any; subgroup severe burns | PT, FT | |
| Cianci/1989 | Patients | 20 | 2 arm: nonrandomized controls burn/routine: 12 (had no access to HBO); burn/routine treatment & HBO: 8 |
18–39 | PT, FT | |
| Cianci/1990 | Patients | 21 | matched pairs burn/routine treatment: 11; burn/routine treatment & HBO: 10, |
19–50 (mean: 30) | PT, FT | |
| Hammar-lund/1991 | Volunteers | 8 | 2 arm cross-over at 10-day interval burn/untreated: 8 burn/HBO: 8 |
<1 | PT | polyurethane film or hydrocolloid |
| Brannen/1997 | Patients | 125 | 2 arm matched pairs; burn/routine treatment: 62 burn/routine treatment & HBO: 63 |
20–50 (mean) | PT, FT | |
| Niezgoda/1997 | Volunteers | 12 | 2 arm randomized; burn/NBO: 6 burn/HBO: 6 |
<1 | PT | hydrocolloid |
| Chong/2013 | Patients | 17 | 2 arm randomized; burn/routine treatment: 9 burn/routine treatment & HBO: 8; non-intubated |
<35 (mean: 13) | PT, FT | bio-occlusive dressing |
| Rasmussen/2015 | Volunteers | 17 | 2 arm crossover: burn/HBO–NBO: 17 burn/NBO–HBO: 17 |
1 | S | |
| Chen/2018 | Patients | 35 | 2 arm retrospective case control; burn/routine treatment: 17 burn/routine treatment & HBO: 18 |
<60 | PT, FT | |
| Wahl/2019 | Volunteers | 21 | 2 arm crossover; burn/HBO–NBO: 12 burn/NBO–HBO: 9 |
1 | S |